Pressrelease – Scandinavian Biopharma announces positive results from its phase I study of a traveler’s diarrhea vaccine

A clinical phase-I study of the company’s new oral traveler’s diarrhea vaccine was recently successfully completed. The vaccine was shown to be safe and well tolerated by the study participants. The prototype vaccine also elicited an intestinal immune response to the vaccine components, in line with what is expected for a protective effect.

The results are very encouraging. A new clinical phase-I study to document the safety and immunogenicity of the final composition vaccine has been initiated.